anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Although serum uric acid (SUA) is a risk factor for cardiometabolic outcome, but it remains unclear which patients with coronary artery disease (CAD) benefit the most from SUA lowering therapy (ULT). The association of SUA level, systemic inflammation and cardiometabolic risk is still unclear. The current study is aimed to examine whether SUA-associated cardiometabolic risk is modulated by systemic inflammation in CAD patients. A total of 16,598 CAD patients with baseline high-sensitivity C-Reactive Protein (hsCRP) and SUA available were included. Baseline and follow-up data were collected. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE), including death, myocardial infarction and stroke. In patients with hsCRP ≥ 2 mg/L, increasing quintiles of SUA were significantly associated with increased rates of 2-year MACCE (adjusted p < 0.001 for trend, p = 0.037 for interaction). Each unit increase in SUA levels was associated with a 11.3% increased risk of MACCE (adjusted p < 0.001, p = 0.002 for interaction). However, in patients with hsCRP < 2 mg/L, increasing quintiles of SUA were not associated with increased MACCE (adjusted p = 0.120). Elevated SUA levels are related to MACCE when hsCRP levels are 2 mg/L or more but not less than 2 mg/L. This finding suggests a potential benefit of combined ULT and anti-inflammation therapy in patients with hyperuricemia and greater systemic inflammation.
Tyrosine kinase inhibitors (TKI) have improved the outcome and life expectancy of patients with chronic myeloid leukemia (CML). Patients are diagnosed with CML at younger ages, and patients treated for CML may become pregnant or choose to breastfeed. The information available to date on the safety of TKIs during pregnancy and lactation and the optimal management of these patients is largely anecdotal, based on personal or small-group experience, and heterogeneous. A panel of interested parties was convened by U.S. Food and Drug Administration to analyze the current data and discuss possible solutions. Possible solutions include prospective data collection, in clinical trials and in routine clinical practice, a more uniform and specific data collection, and greater coordination among involved entities. As patients with cancer are living longer, frequently receiving therapies for extended periods of time (or for life), data on appropriate management of patients through different reproductive phases of life are needed. It is thus time to change our approach for how to study treatment of cancer (including CML) during pregnancy or breastfeeding to develop evidence-based guidelines for safe and effective patient care.
The invention provides a Chinese medicinal formula for treating scald and burn. A medicine prepared according to the formula is prepared from the following important raw materials by weight: 20-30g of bigleaf beautyberry leaves, 10-30g of ligustrum leaves, 15-35g of myrrh, 25-40g of frankincense, 25-30g of safflowers, 40-80g of giant knotweed, 50-100g of coptis roots, 60-80g of ecucalytypus leaves, 20-40g of ostrokrzew kolczasty, 22-60g of plum-leaved holly, 50-80g of amur corktree bark and 60-80g of Chinese angelica. The medicine prepared according to the formula is totally made of traditional Chinese medicines, so that the medicine is free from side effects. The medicine is smeared onto affected areas. The treatment of the scald and the burn by using traditional Chinese medicine is safe. The medicine is convenient to prepare, short in treatment period, quick in response, low in price, and free from toxic and side effects on the skin, and can be used for curing the affected areas on the skin rapidly and effectively. The cure rate is up to 95 percent.
BACKGROUND: Neuroinflammation contributes to degeneration of neurons in people with Parkinson's disease (PD). The concentrations of inflammatory cytokines, IL-1β, IL-6, and TNF-α, are often increased in people with PD and are associated with various non-motor symptoms. Qigong exercise is a mind-body practice which has been used as a rehabilitation intervention for people with PD. A previous study showed a strong association between sleep quality and inflammatory status. This study investigated the effect of Qigong on inflammatory status in people with PD and explored potential relationships between inflammatory status and sleep quality in this population.
METHODS: The study was a randomized controlled trial. A total of 17 participants completed the 12-week intervention (Qigong (n = 8), sham Qigong (n = 9)). Questionnaires were utilized to assess non-motor symptoms, including sleep quality. Inflammatory cytokines were measured by a high sensitivity antibody-based multiplex assay.
RESULTS: After the 12-week intervention, a decreasing trend in the concentrations of IL-1β and IL-6 was found in the Qigong group. Moderate to strong correlations were found between changes in IL-1β concentrations and sleep quality.
CONCLUSION: Inflammation is an important aspect of PD. This study explored the inflammatory status after a mind-body exercise. Further studies need to extend our findings to confirm the effect of Qigong in people with PD.
Many patients with Generalized Anxiety Disorder (GAD) do not benefit or show only partial benefit from current psychotropic therapies. This trial was conducted for the purpose of determining the effectiveness of risperidone as an adjunctive treatment in patients with GAD who demonstrate a less-than-optimal response to their current anxiolytic treatment (either allowed antidepressants, benzodiazepines, or buspirone, or combination). Patients were randomized (patients are assigned different treatments based on chance) to either risperidone or placebo for 4 - 6 weeks of double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage) treatment. Patients randomized to risperidone continued on their current anxiolytic treatment (treatment for anxiety) and received risperidone 0.25 mg per day for the first 3 days, 0.5 mg per day for days 4 through 14, and 1 mg per day for days 15 through 28 of the trial. If clinically indicated, on day 29, the dose could be increased to 2 mg per day for the rest of the trial (4 to 6 additional weeks). At each dose level, risperidone was taken by mouth in a single daily dose. Patients were asked questions every one or two weeks, depending on the phase of the trial, to determine efficacy (effectiveness) and safety. The study hypothesis is that risperidone will be more effective as an adjunct to standard psychotropic treatments for symptoms of Generalized Anxiety Disorder than placebo, as measured by a composite of the four most troubling symptoms identified at baseline.

Risperidone 0.25 mg per day for the first 3 days, 0.5 mg per day for days 4 through 14, and 1 mg per day for days 15 through 28 of the trial. If clinically indicated, on day 29, the dose could be increased to 2 mg per day for the rest of the trial (4 to 6 additional weeks). At each dose level, risperidone was taken by mouth in a single daily dose.
Granules of materials for blending into a mixed feed or premix, which are known to be unstable in mixed feeds and premixes (e.g. thiamines derivs. Amprolium or colistin sulphate) are prepd. by adding to the material 2 wt.% (w.r.t. mixed feed or premix) of Na carboxymethylcellulose, kneading the mixt. with H2O, granulating and drying at up to 80 degrees C.
This is a medical device foam dressing allowing placement away from wound site. It is designed to simplify the bridging application. It is used in combination with the V.A.C. Negative Pressure Wound Therapy System. For each subject, the dressing was applied in compliance with the IFU for 48-72 hours.
Participants will have the implant (filled prior to implantation with approximately 20 microlitres (uL) of the 100 milligrams/millilitres (mg/ml) formulation of ranibizumab \[approximately 2 milligrams (mg) dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their enrollment visit. After the initial fill of the implant with ranibizumab, participants will receive implant refill-exchanges at fixed Q24W intervals.
Pharmaceutical compsns. contg. polyprenylalkenoates are useful as anticancer agents and as therapeutic agents for the treatment of skin diseases, and have low toxicity. Thus, ethyl 3,7,11, 15-tetramethyl- 2,4,6,10,14-hexadecapentaenoic acid was prepared by the Wittig reaction of triethyl phosphonoacetate with 1-p-trisulfonyl-3,7,11- trimethyl-2,6,10-dodecatrien in the presence of tetrahydrofuran in hexane. The anticancer activity of the compds. was demonstrated in mice.
FIELD: medicine. SUBSTANCE: device has shape adapted for fitting it to user teeth. The strip essentially covers the frontal side of at least four teeth and two canine teeth of the user. Anterior sides of additional teeth are also coverable. The strip is wound around teeth ends and to back surface of one or more of anterior four teeth. The strip is manufactured in any shape that allows the canine teeth to protrude outward. Acceptable shapes are essentially trapezoid with stepped sides or with notches or without them and rectangular forms with notches produced with stepped sides or sides having notches. EFFECT: long-time adherence to teeth without sliding. 15 cl, 9 dwg
LY2140023: 80 mg, high particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
PCT No. PCT/NL91/00211 Sec. 371 Date Apr. 19, 1993 Sec. 102(e) Date Apr. 19, 1993 PCT Filed Oct. 23, 1991 PCT Pub. No. WO92/06710 PCT Pub. Date Apr. 30, 1992The invention relates to immunogenic complexes such as two-dimensional lamellae having a honeycomb structure and in particular three-dimensional iscoms, which immunogenic complexes are composed of at least one sterol, one saponin and, in the case of iscoms, also a phospholipid and also, optionally, at least one antigen generating an immune reaction. The saponin used is at least one of the fractions which are derived from Quil A by means of hydrophobic interaction chromatography and have the designations QA 1 to QA 23, as is shown in the figure by the numerals 1 to 23. Preferably, the saponin used is one or more of the fractions derived from Quil A having the designations QA 3, QA 17 and QA 23. As well as relating to the immunogenic complex, the invention also relates to the specific method of preparation of the relevant Quil A fractions, to vaccines which contain such immunogenic complexes and to kits which contain, on the one hand, an (empty) immunogenic complex and, on the other hand, one or more antigenic proteins or peptides having a hydrophobic fragment which may or may not have been synthetically introduced.
After institutional review approval, pregnant women that are scheduled for elective cesarean delivery will be approached by Principal investigator or any of the co-investigators for participation in the study during the the preoperative visit which coincides with the same day of scheduled cesarean in a private patient room. . Prospective subjects will be presenting for their preoperative appointment (same day of scheduled cesarean delivery) in labor and delivery and will be asked to participate in the study. The study will be explained as in the consent form and if agreed patients will elect either to or not to participate in the study after all risks and benefits are explained. Data to be collected will consist of time in minutes of passing flatus, time in minutes of having a bowel movement, hospital length of stay, postoperative nausea, vomiting and presence of ileus (unable to tolerate diet, abdominal distention, no bowel movement nor flatus, abdominal x-ray demonstrating air/fluid levels in bowel). Patients will be contacted once to twice a day for assessment of data points mentioned above. If elected to participate consents will be obtained. Randomization will be done at time of consents. The study's time frame inclusive will be from 2013 till 2016.
System for the trans-dermal introduction includes the first means with the mixture of all active agents. First active agent is contained in the quantity, which ensures the effective therapeutic dose, which must be introduced. Second active agent is contained in the quantity, which is lower than required for the introduction of effective therapeutic dose. System also includes one or several extra-budgetary resources. Each of them contains one active agent (c), selected from those, which is present in the first means. They all are located in the quantity, which is lower than that quantity, which is required for the introduction of effective therapeutic dose. The extra-budgetary resource indicated or the means supply each of the active agents, which are contained in the system in the quantity necessary for obtaining the effective therapeutic dose.
Disclosed is a Chinese medicine prescription for treating talagia, which is prepared from the following active pharmaceutical ingredients by weight: 15g of radix angelicae sinensis, 15g of radix rehmanniae preparata, 12g of cornus officinalis, 15g of white peony root, 30g of achyranthes root, 15g of radix paeoniae rubra, 12g of peach seed, 12g of safflower, 30g of caulis spatholobi, 30g of herba lycopodii, 30g of semen coicis, 20g of rhizoma drynariae, 12g of fructus psoraleae, 30g of  radix dipsaci, 10g of frankincense, 10g of myrrh and 10g of prepared radix glycyrrhizae. The Chinese medicine prescription for treating talagia is provided in that the traditional Chinese physicians think the talagia mostly caused by inherent defect, renal deficiency, emotion disturbance and excessive sexual intercourse. The calcar pedis is the place where the Shenjing point goes, whose pain is caused by kidney deficiency, the liver failing to be nourished, liver controlling tendon, liver-blood deficiency, the tendon failing to be nourished, blood stasis, sukra prameha, cold hygrosis invasion and vein imbalance. For the above disease causes, in the prescription the selected medicines are stressfully required to be Yin meridian medicines for tonifying the liver and the kidney, promoting qi to activate blood, excreting dampness to dissipate cold, and alleviating pain. The active ingredients of the medicines are built up to cooperate the medicines to have the curative effect doubled, which is a Chinese medicine prescription with special efficacy for treating talagia. The Chinese medicine prescription has been clinically applied for many years to cure hundreds of patients, which has the advantages of reliable and obvious curative effect, gentle drug property and no toxic side effect, with effective rate up to 90% and cure rate 80%.
PURPOSE: An agent for preventing adhesions of organs containing pachyman originated from Poria cocos (Fr.) Wolf as a main component is provided which can prevent adhesion of organs caused by surgery operations or surgical injury of human or animals. CONSTITUTION: This anti-adhesion agent for organs is a water soluble or insoluble material obtained from plant polysaccharides or mushroom polysaccharides. The plant polysaccharides are cellulose and the mushroom polysaccharides are polysaccharides of Poria cocos (Fr.) Wolf, Polyporus umbellatus (Pers.) Fries, etc.. The agent is useful in surgery to prevent the formation of post-surgical adhesions and has improved safety to human body.
PROBLEM TO BE SOLVED: To obtain a complex useful for cosmetic and hair cosmetic by combining a phosphoric ester-modified silicone useful as a component for cosmetic formulation, with a specific cationic polymer. SOLUTION: This complex is prepared by formulating a phosphoric ester- modified silicone of formula I [R is a 1-10C hydrocarbon; R<1> is R, formula II (M is an alkali metal; a, b are each 0-50; x is 1-20); l is 0-100; m is 0-500] to a cationic polymer at a molar ratio of 0.1/1-1/0.01. The phosphoric ester- modified silicone is, for example, the compound of formula III. The cationic polymer is, for example, guar gum halogenated hydroxyalkyltrialkylammonium ether or the like. The formulation of this complex to cosmetics attains polyfunctionization and increased performance, as the intrinsic qualities of the cosmetics such as rinse-in-shampoo is retained or improved. It is most suitable as hair cosmetic, in particular.
Carcinogenesis: In carcinogenicity studies, rats and mice were given sumatriptan by oral gavage (rats; 104 weeks) or drinking water (mice; 78 weeks). Average exposures achieved in mice receiving the highest dose (target dose of 160 mg/kg/day) were approximately 184 times the exposure attained in humans after the maximum recommended single intranasal dose of 20 mg. The highest dose administered to rats (160 mg/kg/day, reduced from 360 mg/kg/day during week 21) was approximately 78 times the maximum recommended single intranasal dose of 20 mg on a mg/m2 basis. There was no evidence of an increase in tumors in either species related to sumatriptan administration. Local effects on nasal and respiratory tissue after chronic intranasal dosing in animals have not been evaluated (see WARNINGS).

Mutagenesis: Sumatriptan was not mutagenic in the presence or absence of metabolic activation when tested in 2 gene mutation assays (the Ames test and the in vitro mammalian Chinese hamster V79/HGPRT assay). In 2 cytogenetics assays (the in vitro human lymphocyte assay and the in vivo rat micronucleus assay) sumatriptan was not associated with clastogenic activity.

Impairment of Fertility: In a study in which male and female rats were dosed daily with oral sumatriptan prior to and throughout the mating period, there was a treatment-related decrease in fertility secondary to a decrease in mating in animals treated with 50 and 500 mg/kg/day. The highest no-effect dose for this finding was 5 mg/kg/day, or approximately twice the maximum recommended single human intranasal dose of 20 mg on a mg/m2 basis. It is not clear whether the problem is associated with treatment of the males or females or both combined. In a similar study by the subcutaneous route there was no evidence of impaired fertility at 60 mg/kg/day, the maximum dose tested, which is equivalent to approximately 29 times the maximum recommended single human intranasal dose of 20 mg on a mg/m2 basis. Fertility studies, in which sumatriptan was administered by the intranasal route, were not conducted.
Ribavirin, a broad spectrum antiviral agent, may enhance the antiretroviral activity of didanosine ( ddI ) without a concomitant increase in toxicity. Ribavirin alters the intracellular metabolism of ddI, enhancing the antiretroviral activity of the active form of ddI.

Patients are divided into two cohorts. Subjects will be stratified by age 3 months to \< 24 months and \>= 24 months to 12 years. Fifty % of patients from each age group will be assigned to each cohort. Cohort 1 receives ddI monotherapy for 4 weeks, followed by combination ddl/ribavirin therapy for an additional 20 weeks. Cohort 2 receives combination ddI/ribavirin for 24 weeks. In both cohorts, after study medications are stopped, patients are treated with prescription antiretrovirals for 4 more weeks. \[AS PER AMENDMENT 7/2/96: Note: In each cohort of 10 subjects at least 2 of 5 children from the older half of the cohort will have an ICD p24 antigen at entry.\]
(I) A kit suitable for use in the acute treatment of trigeminal neuralgia is provided, wherein the kit comprises a support, preferably a gum mount, for mounting inside a patient’s mouth, an oral composition, and a reservoir for mounting on the support and for releasing the oral composition, wherein the oral composition comprises a TRPV1 (transient receptor potential cation channel subfamily V member 1, also known as Vanilloid type-1) agonist. Preferably capsaicin, and an orally acceptable diluent. The reservoir is preferably in the form of an absorbent adhesive tape. The TRPV1 may be compound of formula (I), or a physiologically acceptable salt thereof wherein R1 is a methyl group or hydrogen; R2 is hydrogen, C1-4alkyl group, C1-4alkylcarbonyl group or an aryl carbonyl group; A is a substituent as herein defined; n and m are each independently 1, 2 or 3; and p is 0, 1, 2 or 3. A TRPV1 agonist for use in a single application for the acute treatment of trigeminal neuralgia is also provided. A composition comprising 5ml capsicum oleoresin (60%) in 20ml isopropyl rubbing alcohol having a 70% alcohol content is exemplified where the composition is topically applied to the gum mount as herein defined for the treatment of trigeminal neuralgia.
The invention pertains to the bio-pharmaceutical field and relates to a medicine combination for treating tumor. The tumor is the worldwide No. 2 killer of human being and the drug resistance is one of the difficulties in the treatment of the tumor diseases. Therefore, to find a chemical compound which can reduce drug resistance is one of the hot topics in the study field of tumor disease. The invention provides the medicine combination for treating tumor and the medicine combination comprises nucleic acid with a gene sequence of 5'-GCCAGUGGAGGCUUCCAGG-3' or 5'-GCCAGTGGAGGCTTCCAGG-3' and daunomycin. The application of the nucleic acid and the daunomycin can dramatically reduce the drug resistance of tumor cells.
Breast cancer is the second most common cancer worldwide and the fifth cause of death from cancer overall (522,000 deaths) and it is the most frequent cause of cancer death in women in less developed regions.In developed countries between 6 and 10 % of women will have metastatic disease when diagnosed with breast cancer ; in developing countries this percentage can reach 60 %. Depending on initial stage, tumor biology, and type of treatment scheme received, between 30 and 50 % of women with early breast cancer will relapse. Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) and, thereby, blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4. As a result, Pertuzumab inhibits ligandinitiated intracellular signaling through two major signal pathways, mitogenactivated protein (MAP) kinase, and phosphoinositide 3-kinase (PI3K). Inhibition of these signaling pathways can result in cell growth arrest and apoptosis, respectively. In addition, Pertuzumab mediates antibody-dependent cellmediated cytotoxicity (ADCC). Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular 286 dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein 287 (HER2). Pertuzumab inhibits ligandinitiated intracellular signaling through two 299 major signal pathways, mitogen-activated protein (MAP) kinase and phosphoinositide 3-kinase 300 (PI3K). Hence we have planned this study which is a Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel study to Evaluate the Efficacy and Safety of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) with Reference Pertuzumab (Perjeta®, Genentech Inc.,) in Previously Untreated Patients with HER2 Positive Metastatic Breast Cancer.